SelectScience InterviewsLab Automation

Labcyte Echo 550 Accelerates Drug Discovery at the Cancer Research UK Manchester Institute

18 Jul 2017
Labcyte Echo 550 Accelerates Drug Discovery at the Cancer Research UK Manchester Institute

This video describes how acoustic liquid dispensing, using the Labcyte Echo® 550, is being used at the Cancer Research UK Manchester Institute and is helping to accelerate compound screening. Learn how the technology reduces the volume of compound needed for each experiment, thus enabling compounds to last longer and more data to be produced. The Institute hopes to use acoustic dispensing to help develop compounds that can be used as a start-point to design new targeted therapies for use in a personalized medicine setting.

Access™ Laboratory Workstation

Small-Scale Automation with Large-Scale Results   Access™ laboratory workstations multiply the benefits of the Echo® liquid handler by improving overall assay throughput and reproducibility. With the ability to integrate a variety of devices and the modularity to scale when needed, each workstation offers the flexibility required by frequently-changing assay requirements.  All Access workstations are optimized at install and include all safety mechanisms required for CE compliance. Access workstations use Labcyte Tempo™ automation control software to manage the system configuration and schedule automated routines. Protocols created from Echo® software applications can be imported into Tempo™ software and quickly converted into fully automated routines. Support for a Range of Applications Assay ready plate preparation Lead optimization and secondary screening assays High-throughput gene expression assays Automated protein crystallography setup

(7)

Echo® 550 Liquid Handler

Beckman Coulter Life Sciences

Imagine preparing assay plates for siRNA screening, compound screening with biochemical and cell-based assays, PCR reactions and more all on a single liquid handling platform, with no tips and no cross-contamination. Labcyte has developed new acoustic droplet ejection (ADE) parameters that deliver built-in intelligence to enable users to transfer many different fluid types from a single instrument. All Echo systems come pre-calibrated so that you can switch among different fluid types with just a click of the mouse. No further adjustment is required for you to be productive immediately. These developments combine the latest discoveries in wavelength, power and timing requirements for ADE with real-time fluid measurement at multiple points during a run. The resulting algorithms solve some of the most significant liquid handling challenges with volatile, low-surface tension and/or meniscus-shifting fluids. Volumetric accuracy and precision for all fluids tested so far—including buffers, nucleic acid and protein solutions, surfactants, serum and cell culture media—are comparable to established performance with DMSO. The Echo® 550 liquid handler introduced the world to acoustic droplet ejection (ADE). This award-winning instrument remains the proven choice for low-volume liquid handling in leading pharmaceutical and biotechnology companies worldwide. Like the Echo 520 and Echo 555 liquid handlers, the Echo 550 uses "touchless" ADE transfer technology. ADE uses sound energy to transfer 2.5 nL droplets from Echo-qualified 384- and 1536-well source plates into 96-, 384-, 1536- and 3456-well destination plates. This unique touchless technology eliminates consumable tip costs, washing, and cross-contamination. Unsurpassed volumetric precision (≤ 8% CV) and accuracy (≤ 10% CV) ensure superior results. Independent studies have shown that Echo liquid handlers eliminate false negatives due to sample loss on tip surfaces in low-concentration transfers. Like the Echo 555 liquid handler, the Echo 550 liquid handler reports both fluid volume and DMSO hydration. Applications: Compound management Compound screening siRNA screening Biochemical assays Cell-based assays PCR Genotyping Gene expression

(22)

Other videos from SelectScience

Links

Labcyte Echo 550 Accelerates Drug Discovery at the Cancer Research UK Manchester Institute